Concorde Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Concorde Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,737	Closed	-$361K	–	198
2021 Q1	$361K	Buy	5,737 +828	+17%	+$51.5K	0.21%	124
2020 Q4	$305K	Sell	4,909 -19	-0.4%	-$1.17K	0.17%	103
2020 Q3	$296K	Buy	+4,928	New	+$297K	0.17%	132
2020 Q2	–	Sell	-4,569	Closed	-$255K	–	124
2020 Q1	$255K	Buy	+4,569	New	+$279K	0.26%	78
2017 Q4	–	Sell	-3,332	Closed	-$212K	–	119
2017 Q3	$212K	Buy	+3,332	New	+$195K	0.18%	135

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Concorde Asset Management's BMY Position: Q2 2021 in Review

Concorde Asset Management sold out of Bristol-Myers Squibb (BMY) in Q2 2021, closing a stake of 5,737 shares — an estimated $361K sold.

Concorde Asset Management first reported a position in BMY in Q3 2017 and held it in 5 quarters. The position peaked at $361K in Q1 2021. 2,369 funds tracked by Wall St. Rank hold BMY as of Q2 2021.

Concorde Asset Management reported no remaining Bristol-Myers Squibb position as of Q2 2021 after selling out during the quarter.
Concorde Asset Management sold 5,737 Bristol-Myers Squibb shares in Q2 2021, an estimated $361K.
Concorde Asset Management first reported a position in Bristol-Myers Squibb in Q3 2017 and held it in 5 quarters.
Concorde Asset Management's Bristol-Myers Squibb position peaked at $361K in Q1 2021.
2,369 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2021.

Based on Concorde Asset Management's 13F filing for Q2 2021, filed 20 Jul 2021.